Bone Marrow Niche-Inspired, Multi-Phase Expansion of Megakaryocytic...

Event Details
  • Date/Time:
    • Tuesday January 19, 2010
      10:00 am - 11:00 am
  • Location: IBB Suddath Rm. 1128
  • Phone:
  • URL:
  • Email:
  • Fee(s):
    N/A
  • Extras:
Contact
James Godard
IBB
Contact James Godard
404-894-8896
Summaries

Summary Sentence: William M. Miller, Ph.D. - Northwestern University

Full Summary: Faculty Host: Michelle Dawson, 404.894.5192

Bone Marrow Niche-Inspired, Multi-Phase Expansion of Megakaryocytic Progenitors with High Polyploidization Potential

Abstract:
Producing platelets from CD41+ megakaryocytic (Mk) cells derived from cultured blood stem and progenitor CD34+ cells would increase the supply of rare blood types and decrease the risk from blood-borne pathogens. However, producing one transfusion dose of 500 billion platelets using current technology would require 5-10 umbilical cord blood harvests or more than a full CD34+ cell harvest from the peripheral blood of donors pretreated with cytokines, so the ex vivo platelet yield must be increased by several orders of magnitude. Because there are profound changes in cell physiology, regulation, and gene expression during Mk commitment and maturation, optimal conditions will differ greatly for the processes of Mk progenitor expansion, Mk cell production, and terminal maturation (polyploidization and proplatelet formation). Inspired by gradients of increasing pH and pO2 with increasing Mk maturation in the bone marrow, we showed that low pH and low pO2 enhance Mk progenitor production, while supervascular pH and pO2 increase Mk ploidy (and platelet-producing potential). We also showed that the vitamin nicotinamide greatly increases Mk ploidy and proplatelet formation in culture. We are developing a 3-step process for Mk cell expansion and maturation with conditions tailored for each step. We identified cytokines in cultures at pH 7.2 and 5% O2 that expand Mk progenitors from 0.01 to 3.5 CD34+CD41+ cells per input CD34+ cell at day 11, while increasing purity from 1% to 17%. However, Mk clonogenic capacity decreased after day 5. Shifting cells to pH 7.4 and 20% O2 at day 5 yielded up to 14 mature Mks per input cell. Simultaneous addition of nicotinamide decreased Mk production, but more than doubled the fraction of high-ploidy (≥ 8N) Mk cells to 40%. We anticipate that subsequent optimization of cytokines for mature Mk production and delayed nicotinamide addition will greatly increase high-ploidy Mk cell production. We hypothesize that nicotinamide increases Mk cell ploidy by inhibiting the SIRT1/2 histone/protein deacetylases. Understanding the underlying mechanisms would facilitate regulatory approval for using nicotinamide to produce platelets for transfusions and may lead to the discovery of even more effective conditions for Mk polyploidization.

Faculty Host: Michelle Dawson, 404.894.5192

Additional Information

In Campus Calendar
No
Groups

Parker H. Petit Institute for Bioengineering and Bioscience (IBB)

Invited Audience
No audiences were selected.
Categories
Seminar/Lecture/Colloquium
Keywords
IBB, seminar
Status
  • Created By: Alyceson Andrews
  • Workflow Status: Draft
  • Created On: Feb 16, 2010 - 9:48am
  • Last Updated: Oct 7, 2016 - 9:50pm